Black Diamond Therapeutics Stock (NASDAQ:BDTX)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$2.89

52W Range

$1.62 - $7.66

50D Avg

$4.41

200D Avg

$4.89

Market Cap

$168.95M

Avg Vol (3M)

$1.23M

Beta

2.48

Div Yield

-

BDTX Company Profile


Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

54

IPO Date

Jan 31, 2020

Website

BDTX Performance


BDTX Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-86.46M$-92.83M$-126.87M
Net Income$-82.44M$-84.52M$-123.20M
EBITDA$-86.46M$-95.06M$-125.60M
Basic EPS-$-2.33$-3.40
Diluted EPS-$-2.33$-3.40

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
RVMDRevolution Medicines, Inc. Warrant
STOKStoke Therapeutics, Inc.
ALECAlector, Inc.
ADAPAdaptimmune Therapeutics plc
BCELAtreca, Inc.
PASGPassage Bio, Inc.
FIXXQ32 Bio Inc.